By Sabela Ojea
Shares of Xeris Biopharma climbed after the company guided for higher revenue in 2025.
The stock was up 17%, to $4.41, in Thursday trading, which is equivalent to the highest close since June 28, 2021. Shares have plunged 81% over the past 12 months.
The biopharmaceutical company projected full-year revenue of $255 million to $275 million, representing growth of over 30% at the mid-point range.
The Chicago company also expects adjusted earnings before interest, taxes, depreciation and amortization to remain positive going forward, Finance Chief Steven Pieper said.
"Our accelerating revenue growth, coupled with our attractive and improving margin profile and disciplined capital allocation, will result in a financially transformative 2025 for Xeris," Pieper said.
The company's outlook came as it reported a significant increase in product revenue in the fourth quarter.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
March 06, 2025 12:10 ET (17:10 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。